<DOC>
	<DOCNO>NCT01398033</DOCNO>
	<brief_summary>There poor life expectancy poor prognosis limb salvage patience stenosis occlusion low limb . To date small number patient could help medication surgery . The indication stent placement poor primary result follow percutaneous transluminal angioplasty evidence flow-limiting dissection . The primary success rate stent placement 80 % 90 % . One far inconsistent discuss problem occurrence in-stent restenosis expect 20 % 78 % treated lesion , depend stent use . Using percutaneous transluminal angioplasty treatment in-stent restenosis , restenosis reoccurs 70 % 80 % case . The aim study analyse primary success long term result angioplasty use drug-coated balloon ( paclitaxel ) compare non-coated balloon treatment in-stent restenosis lower limb artery .</brief_summary>
	<brief_title>Paclitaxel-Coated Versus Uncoated Balloon Treatment Below-the-Knee In-Stent-Restenosis</brief_title>
	<detailed_description>In prospective , double-blind , randomised , multi-centre study use already certify coat balloon uncoated balloon evaluate patient in-stent restenoses/reocclusions low limb artery . The whole lesion length cover balloon proximal distal overlap lesion minimum 5mm assure . Based current literature average restenoses rate lower limb artery percutaneous transluminal angioplasty in-stent restenosis 70 % 6 month . Assuming restenosis rate reduces 30 % percutaneous transluminal angioplasty use drug-coated balloon , significance level Alpha=0.05 ( bilateral ) power Beta=0.8 , enrolment 100 patient require order show significant difference treatment group , consider dropout rate 30 % . The choice treatment distribute randomised , double blind procedure . The study duration per patient 2 year . Clinical follow-up evaluation take place 3 6 month 1 2 year . After 3 month 12 month angiography target vessel perform .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age 50 year Signed declaration consent Subject willing able participate plan evaluation study protocol Arterial occlusion disease stage 3 6 RutherfordBecker Subject instent stenosis 70 % vascular lumen diameter tibioperoneal trunc and/or posterior tibial artery and/or anterior tibial artery and/or peroneal artery . Here vascular segment , affect continuous ( include stent ) , proximal distal stent relevant ( ) stenosis , treat accord randomisation The length target lesion ( ) exceed 290mm In total four drugcoated balloon enough treat maximum two lesion The target lesion 's lumen diameter 2.0mm 3.5mm Successful passage wire target lesion randomisation Coagulopathy Pregnancy Contraindications antiplatelet heparin Factors exclude follow Life expectancy &lt; 12 month Known allergy contrast agent and/or Clopidogrel and/or Aspirin &gt; 50 % stenosis distal target lesion Visible thrombus target lesion Lytic therapy 72 hour plan intervention Aneurysm femoral popliteal artery Intervention focal lesion femoral popliteal artery may carry treatment target lesion order enhance inflow low limb</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>infrapopliteal artery</keyword>
	<keyword>In-stent stenosis</keyword>
	<keyword>long lesion</keyword>
	<keyword>drug-coated balloon</keyword>
</DOC>